NOVEL THERAPIES FOR METABOLIC COMPLICATION IN PATIENTS WITH LIPODYSTROPHIES

脂肪营养不良患者代谢并发症的新疗法

• 批准号: 7606355
• 负责人: Abhimanyu Garg
• 金额: $ 0.46万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606355
• 关键词: Adipose tissue; Affect; Agonist; Cholic Acid; Cholic Acids; Clinical Trials; Complication; Computer Retrieval of Information on Scientific Projects Database; Condition; Diabetes Mellitus; Disease; Dyslipidemias; Fat-Restricted Diet; Fatty Liver; Funding; Grant; Hypertriglyceridemia; Institution; Insulin Resistance; Intervention; Leptin; Lipodystrophy; Metabolic; Patients; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Purpose; Replacement Therapy; Research; Research Personnel; Resources; Safety; Source; Therapeutic; United States National Institutes of Health; improved; novel; therapy design

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Lipodystrophies are a heterogeneous group of disorders characterized by selective loss of adipose tissue. Affected patients frequently have metabolic complications related to insulin resistance such as diabetes, hypertriglyceridemia and hepatic steatosis. Due to the extreme insulin resistance, treatment of these conditions represents a major therapeutic challenge. There is marked paucity of clinical trials evaluating treatment options in patients with lipodystrophy. The purpose of the study is to examine the safety and efficacy of various novel interventions designed to improve or resolve diabetes, dyslipidemia and fatty liver in these patients. The specific interventions to be examined are low fat diet, leptin replacement therapy, cholic acid therapy and treatment with the peroxisome proliferator activated receptors (PPAR) agonist, pioglitazone.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 脂肪营养不良是一组异质性疾病，其特征是脂肪组织的选择性丧失。 受影响的患者经常患有与胰岛素抵抗有关的代谢并发症，例如糖尿病，高甘油三酸酯和肝脂肪变性。 由于极端的胰岛素耐药性，对这些疾病的治疗代表了一个主要的治疗挑战。 在评估脂肪营养不良患者的治疗选择的临床试验中，临床试验很少出现。 该研究的目的是检查这些患者旨在改善或解决糖尿病，血脂异常和脂肪肝的各种新型干预措施的安全性和功效。 要检查的特定干预措施是低脂饮食，瘦素替代疗法，胆汁酸治疗和过氧化物酶体增殖物激活受体（PPAR）激动剂Pioglitazone的治疗。